SOURCE: CDEX Inc.

CDEX Inc.

December 14, 2009 09:05 ET

ValiMed™ MVS Draws Large Crowds and High Praise at ASHP Conference

ValiMed MVS Should Be Required at All Hospitals - Emily Jerry Foundation

TUCSON, AZ--(Marketwire - December 14, 2009) - CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com) announces that it presented the lifesaving capability of its ValiMed™ MVS (Medication Validation System) with new onsite data collection options to a great number of interested hospital pharmacists and safety specialists at the Las Vegas ASHP Conference (December 7-9, 2009). Worldwide studies continue to show that human errors in the compounding of high-risk medications occur frequently and result in permanent harm to patients and that the diversion of medical narcotics is a continuing problem. ValiMed MVS is a technological safety net that provides protection for patients, pharmacists and hospitals.

"I saw the ValiMed MVS demonstrated at the ASHP Conference and my conclusions are that it should be required at all hospitals -- technology like this could have prevented the death of my daughter," said Chris Jerry, President of the Emily Jerry Foundation (www.emilyjerryfoundation.org). "At the Conference, Dennis Quaid talked about the frequency of human errors and the need for technology to protect against them. From what I have seen, ValiMed is the only technology available today that prevents harm to patients from human errors in the compounding of high-risk medications. I believe that those hospitals which have adopted the ValiMed MVS as part of their Medication Safety Programs have set the standard of care and all hospitals should follow suit."

"With the new policy of zero tolerance to medication errors announced by the Joint Commission the interest in ValiMed MVS was high -- human errors happen," said Greg Firmbach, CDEX Senior VP. "We had our largest number of CDEX representatives ever at a conference and presented the ValiMed MVS capabilities to the largest number of hospital representatives ever at the booth. It looks like 2010 is stacking up to be an exciting year as hospital budgets are beginning to loosen and the ValiMed MVS Pay-Per-Use Pricing gets into full swing."

About CDEX

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Malcolm Philips at mphilips@cdex-inc.com.

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "believes," "should," "intends," and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Contact Information